| |
ICON has the experience and expertise to overcome the challenges in patient recruitment and retention to deliver study success. Explore ICON's DCT capabilities. 
|
|
Today’s Big NewsDec 7, 2023 |
|
Explore new possibilities with Fortrea. Oncology drug development informed by years of insights and powered by our agile approach to clinical trials. Explore Agility. 
|
|
| By Annalee Armstrong AbbVie will delve deeper into neuroscience and psychiatric disease with the $8.7 billion acquisition of Cerevel Therapeutics. |
|
|
|
By Annalee Armstrong AbbVie’s $8.7 billion acquisition of Cerevel will help fill in gaps in the Chicago pharma’s pipeline with new areas to explore in neuroscience, but will regulators play ball? |
By Nick Paul Taylor Sanofi has tipped three “pipeline-in-a-product” assets to generate 5 billion euros ($5.4 billion) a year or more. The forecasts are part of a set of predictions intended to justify the drugmaker’s decision to funnel cash into key programs rather than increase its operating profit margin. |
Sponsored by Cell Signaling Technology CST fellow Amrik Singh outlines some of the key progress being made around CAR-T therapy and the impact that this highly specialized technique can have on cancer patients, even those who have been previously unresponsive to other forms of treatment. |
|
Quickly customize your ADME/DMPK & Drug-Drug Interaction study quotes based on your needs and end goals... View Options >> 
|
|
By Gabrielle Masson By the end of the year, biopharmas are projected to have raised about $24 billion across about 840 transactions—the lowest tally in four years, according to a new PitchBook analysis. |
Sponsored by IQVIA IQVIA’s new technologies are changing clinical trials, reducing the administrative burden on staff and improving insights for sponsors. |
By Eric Sagonowsky Responses to Regeneron's bispecific linvoseltamab have risen but so have adverse events and deaths associated with the multiple myeloma drug. |
By Nick Paul Taylor Merck & Co. has cracked open the casket of its failed phase 2 TIGIT clinical trial, revealing that neither combination featuring its antibody vibostolimab improved progression-free or overall survival. |
By Max Bayer ARTBIO has closed a $90 million series A round less than six months after launching. The round was led by Third Rock Ventures and an undisclosed healthcare fund. |
By Gabrielle Masson Hepion Pharmaceuticals is trying to stay afloat as the biotech’s CEO hits the exit and the company seeks strategic alternatives, leaving the fate of a phase 2b trial for non-alcoholic steatohepatitis (NASH) up in the air. |
By Helen Floersh Pairing Dupixent with PD-1 inhibitors slowed tumor growth in mouse models and stabilized disease in some patients in a small clinical trial. |
By Andrea Park About half a year after announcing its intent to acquire a South Korean maker of tubeless insulin pump technology, Medtronic is scrapping the deal. |
By Angus Liu Merck has called it quits on another attempt to enhance its powerful PD-1 inhibitor Keytruda in non-small cell lung cancer just as its TIGIT program goes up in flames. |
By Joseph Keenan Novartis has joined the likes of Eli Lilly and others by investing in the AI technology developer Yseop as part of a push to automate elements of clinical trial report writing that could speed drug development efforts. |
By Dave Muoio Generative AI, outsourcing and skilled labor retention are among the focal points provider and payer executives will need to keep in their crosshairs. |
Fierce podcasts Don’t miss an episode |
| In this episode of "The Top Line," we're highlighting the remarkable women featured in our annual Fiercest Women in Life Sciences special report. The list comprises 10 trailblazers changing the leadership landscape in pharma, biotech and medtech. |
|
|---|
|
|
Whitepaper qPCR Assay Design - Quantify microbial biomarkers with high sensitivity and dynamic range Sponsored by: Diversigen |
Whitepaper Streamline your clinical cell therapy with our GMP-compliant ribonucleoprotein (RNP) manufacturing as you scale up without compromising on quality to tackle complex regulatory requirements. Sponsored by: Aldevron |
Whitepaper If you find yourself grappling with bioanalytical challenges during the drug development process, rest assured that these obstacles can be overcome - discover more! Sponsored by: Sannova Analytical |
Whitepaper Discover how cloud-based HPC and AI can transform drug discovery and accelerate time-to-market. Download the free solution brief to learn more. Sponsored By: AWS, NVIDIA, and Rescale |
Executive Summary By 2030, the global demand for biologics is projected to grow at a CAGR of 8.7% and the challenges, risks, and costs of bringing large molecule products to market are growing exponentially. Sponsored by: ThermoFisher Scientific |
Whitepaper Learn about the untapped power of AI-driven insights — where innovation meetings precision, effortlessly unlocking benefits for your organization. Sponsored by: Planisware |
Whitepaper Medical devices & consumer wearables are starting to overlap, creating risks & opportunities for traditional medical device companies as well as consumer wearables manufacturers. This paper explores pros and cons from both perspectives. Sponsored by: Blue Matter Consulting |
Whitepaper Improving efficiency and productivity in biologics manufacturing is a longstanding goal within today’s industry, especially now as new and increasingly complex molecules are fundamentally changing technological and operational approaches to drug development. Process intensification can help accelerate this pace of innovation through advanced process development techniques and high productivity manufacturing platforms. Sponsored by: Lonza |
Whitepaper As a leader of technology transfer activities in the industry, Lonza understands the challenges associated with this critical step. Download this White Paper today to learn more. Sponsored by: Lonza |
eBook Emulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
Whitepaper A critical area to consider in selecting a CDMO is their ability to successfully complete technology transfers, which involves an intricate set of activities and disciplines that, if done incorrectly, could result in delays and failures that impact the overall success of your end product. Recognizing what it takes to complete this process effectively and efficiently is crucial to selecting the best partner for your project and product needs. This white paper delivers an analysis of critical success factors for effective technology transfer. Sponsored by: Lonza |
| |
|
